Quality Criteria for the Website of the Paul-Ehrlich-Institut

About us

The Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines is a senior federal authority that reports to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG).

The institute with its office at Langen near Frankfurt is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute.

Our requirements for our webcontent

The Paul-Ehrlich-Institut publishes information in the fields of health service and research. The information conforms to the current state of knowledge. All content is created by experts of the institute. Before publication, this content is also double-checked by experts of the PEI. Every text to be published is reviewed by a member of the leadership team. The sources of information are specified (scientific publications, legal basis).

The members of the leadership team are heads of the Paul-Ehrlich-Institute's divisions with scientific and/or medical expertise.

- Presentation of the Leadership Team

The information published on our internet pages is designed to support the relations between doctors and patients. However, it cannot replace them.

The quality of the information in the fields of health service and research is dependent on how up-to-date it is. For this reason, we publish the date of the last update of our content.

Confidentiality of data is a prerequisite for trust. To achieve this, the basic principles contained in our privacy policy apply:

- Privacy Policy

The structure of our website

The content and structure of the new website are the result of analyses of target groups and the environment. They follow the best practices of digital communication. Complex content of the PEI is clearly structured and, in addition, presented for the general public by means of FAQ, a glossary, and video clips.

Besides, the website is optimised for use on mobile devices. Special attention is paid to accessibility of the content by persons with impairments.

The contact details of the editor's office and professional contacts are available on each web page of the PEI.:

- Imprint
- Contact
- Statement on Accessibility

How our website is funded

The Paul-Ehrlich-Institut as the operator of the website www.pei.de does not pursue any commercial aims. It does not publish any commercials, nor does it receive any income from commercials.

The PEI's revenue and expenditure are laid down in the federal budget. The conforming management of the budget is audited by the BMG (Federal Ministry of Health) and the Bundesrechnungshof (Federal Audit Office). The PEI's revenue is mainly earned from fees collection for official duties (statutory Cost Regulation for Official Duties of the Paul-Ehrlich-Institut pursuant to the German Medicinal Products Act, Statutory Cost Regulation relating to Vaccines for Veterinary Use). Additional revenue is earned from orders received from the European Medicines Agency (EMA) and other authorities in the field of health care (e.g. other medicines agencies).

Research at the Paul-Ehrlich-Institut is financially supported by external institutes including the European Commission or the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).

- Research and Third-Party Funding

The testing laboratory for in vitro diagnostic devices (PEI-IVD) does not operate in a profit-oriented manner, even if it is treated as a commercial enterprise ("Betrieb gewerblicher Art") from the point of view of the German tax laws PEI-IVD provides services for notified bodies pursuant to the European laws governing medical devices. It covers its costs by revenue in accordance with the rates in the PEI-IVD price list.